Theories concerning the pathogenesis of the acute charcot foot suggest future therapy

Current Diabetes Reports

Volumn 5, Issue 6, 2005, Pages 430-435

  Jeffcoate, William J ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CURCUMIN; CYTOKINE; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN INHIBITOR;

BIOMECHANICS; BLOOD VESSEL CALCIFICATION; CELL ACTIVATION; CLINICAL FEATURE; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE COURSE; DISEASE PREDISPOSITION; DISLOCATION; FOOT DISEASE; FOOT INJURY; HUMAN; HYPEREMIA; INFLAMMATION; LEG FRACTURE; MEDICAL DECISION MAKING; NEUROPATHIC JOINT DISEASE; OSTEOARTHROPATHY; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; PATHOGENESIS; REVIEW; SENSATION; THEORY; TREATMENT PLANNING; WEIGHT BEARING;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS; ARTHROPATHY, NEUROGENIC; DIABETIC FOOT; DIABETIC NEUROPATHIES; HUMANS; MODELS, THEORETICAL; PROGNOSIS;

EID: 29644443632     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-005-0050-z     Document Type: Review

References (59)

1. Jeffcoate W, Lima J, Nobrega L: The Charcot foot. Diabet Med 2000, 17:253-258.
2. Rajbhandari SM, Jenkins RC, Davies C, Tesfaye S: Charcot neuroarthropathy in diabetes mellitus. Diabetologia 2002, 45:1085-1096.
3. Nabarro JD: Diabetes in the United Kingdom: a personal series. Diabet Med 1991, 8:59-68.
4. Fabrin J, Larsen K, Holstein PE: Long-term follow-up in diabetic Charcot feet with spontaneous onset. Diabetes Care 2000, 23:796-800.
5. Saltzman CL, Hagy ML, Zimmerman B, et al.: How effective is intensive nonoperative initial treatment of patients with diabetes and Charcot arthropathy of the feet? Clin Orthop Relat Res 2005, 435:185-190.
6. Sinacore DR, Withrington NC: Recognition and management of acute neuropathic (Charcot) arthropathies of the foot and ankle. J Orthop Sports Phys Ther 1999, 29:736-746.
7. Gazis A, Pound N, Macfarlane R, et al.: Mortality in patients with diabetic neuropathic osteoarthropathy (Charcot foot). Diabet Med 2004, 21:1243-1246.
8. Mitchell JK: On a new practice in acute and chronic rheumatism. Am J Med Sci 1831, 8:55-64.
9. Charcot JM: Sur quelques arthropathies qui paraissent dépendre d'une lésion cerveau ou de la mouelle épinière. Arch Physiol Norm Pathol 1868, 1:161-178.
10. Charcot JM, Féré C: Affections osseuses et articulaires du pied chez les tabétiques (pied tabétique). Arch Neurol 1883, 6:305-309.
11. Transaction of the International Medical Congress [no authors listed]. 1881, 8:128-129.
12. Jordan WR: Neuritic manifestations in diabetes mellitus. Arch Intern Med 1936, 57:307-366.
13. Berliner medicinische Gesellschaft [no authors listed]. Sitzung vom 17 November. Berliner Klinische Wonchenschr 1886.
14. Stevens MJ, Edmonds ME, Foster AV, Watkins PJ: Selective neuropathy and preserved vascular responses in the diabetic Charcot foot. Diabetologia 1992, 35:148-154.
15. Young MJ, Marshall A, Adams JE, et al.: Osteopenia, neurological dysfunction, and the development of Charcot neuroarthropathy. Diabetes Care 1995, 18:34-38.
16. Henderson VE: Joint affectations in tabes dorsalis. J Pathol 1905, 10:211-263.
17. Leriche R: Sur quelques maladies osseuses et articulaires d'origine vaso-motrice et sur leur traitement. Bull Mem Soc Nat Chir 1927, 53:1022-1030.
18. Marinescu G, Bruch H: Zur kenntnis der gelenkstörungen bei tabes. Zeitschr F Klin Med 1937, 132:178-182.
19. Foster DB, Bassett RC: Neurogenic arthropathy associated with (Charcot joint) with diabetic neuropathy: report of two cases. Arch Neurol Psychiat 1947, 57:173-185.
20. Martin MM: Charcot joints in diabetes mellitus. Proc Roy Soc Med 1952, 45:503-506.
21. Martin MM: Involvement of autonomic nerve fibres in diabetic neuropathy. Lancet 1953, 1:560-565.
22. Archer AG, Roberts VC, Watkins PJ: Blood flow patterns in diabetic neuropathy. Diabetologia 1984, 27:563-567.
23. Ziegler R: Diabetes mellitus and bone metabolism. Horm Metab Res Suppl 1992, 26:90-94.
24. Cundy T, Edmonds ME, Watkins PJ: Osteopenia and metatarsal fractures in diabetic neuropathy. Diabet Med 1985, 2:461-464.
25. Kayath MJ, Dib SA, Vieia JG: Prevalence and magnitude of osteopenia associated with insulin-dependent diabetes mellitus. J Diabet Complications 1994, 8:97-104.
26. Jeffcoate W: Vascular calcification and osteolysis in diabetic neuropathy - is RANK-L the missing link ? Diabetologia 2004, 47:1488-1492.
27. Forst T, Pfutzner A, Kann F, et al.: Peripheral osteopenia in adult patients with insulin-dependent diabetes mellitus. Diabet Med 1995, 12:874-879.
28. Rix M, Andresaasen H, Eskilden P: Impact of peripheral neuropathy on bone density in patients with type 1 diabetes. Diabetes Care 1999, 22:827-831.
29. Petrova NL, Foster AV, Edmonds ME: Calcaneal bone mineral density in patients with Charcot neuropathic osteoarthropathy: differences between type 1 and type 2 diabetes. Diabet Med 2005, 22:756-761.
30. Herbst SA, Jones KB, Saltzman CL: Pattern of diabetic neuropathic osteoarthropathy associated with the peripheral bone mineral density. J Bone Joint Surg Br 2004, 86:378-383.
31. Hofbauer LC, Heufelder AE: The role of receptor activator of nuclear factor kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 2005, 85:2355-2363.
32. Khosla S: Minireview: the OPG/RANKL/RANK system. Endocrinology 2001, 142:5050-5055.
33. Schoppet M, Preissner KT, Hofbauer LC: RANK ligand and osteoprotegerin. Paracrine regulators of bone metabolism and vascular function. Arterioscl Thromb Vasc Biol 2002, 22:549-553.
34. Ashcroft AJ, Davies FE, Morgan GJ: Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol 2003, 4:284-292.
35. Rogers A, Eastell R: Circulating osteoprotegerin (OPG) and receptor activator for NFkappaB ligand (RANKL): clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005, Aug 16; [Epub ahead of print].
36. Browner WS, Lui LY, Cummings SR: Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001, 86:631-637.
37. Knudsen ST, Foss CH, Poulsen PL, et al.: Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003, 149:39-42.
38. Suzuki K, Kurose T, Takizawa M, et al.: Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease off bone mineral density. Diabetes Res Clin Pract 2005, 68:117-125.
39. Edmonds ME, Morrison N, Laws JW, Watkins PJ: Medial arterial calcification and diabetic neuropathy. BMJ 1982, 284:928-930.
40. Goebel FD, Fuessl HS: Monckeberg's sclerosis after sympathetic denervation in diabetic and non-diabetic subjects. Diabetologia 1983, 24:347-350.
41. Sinha S, Munichoodappa C, Kozak GP: Neuro-arthropathy (Charcot joints) in diabetes mellitus: a clinical study of 101 cases. Medicine (Baltimore) 1972, 51:191-210.
42. Clouse ME, Gramm HF, Legg M, Flood T: Diabetic osteoarthropathy: clinical and roentgenographic observations in 90 cases. AJR Am J Roentgenol 1974, 121:22-33.
43. Purewal TS: Charcot's diabetic neuroarthropathy: pathogenesis, diagnosis and management. Pract Diab Int 1996, 13:88-91.
44. Bucay N, Sarosi I, Dunstan CR, et al.: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 1:1260-1268.
45. Hofbauer LC, Schoppet M: Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet 2001, 358:257-259.
46. Demer LL, Tintut Y, Parhami F: Novel mechanisms in accelerated vascular calcification in renal disease patients. Curr Opin Nephrol Hypertens 2002, 11:437-443.
47. Schoppet M, Al-Fakhari N, Franke FE, et al.: Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004, 89:4101-4112.
48. Collin-Osdoby F: Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004, 95:1046-1057.
49. Pennisi P, Signorelli SS, Riccobene S, et al.: Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporosis Int 2004, 15:389-395.
50. Edelman SV, Kosofsky EM, Paul RA, Kozak GP: Neuro-arthropathy (Charcot's joints) in diabetes mellitus following revascularisation surgery. Arch Intern Med 1987, 147:1504-1508.
51. Fleischli JE, Anderson RB, Davis WH: Dorsiflexion metatarsal osteotomy for treatment of recalcitrant diabetic neuropathic ulcers. Foot Ankle Int 1999, 20:80-85.
52. Gerstenfeld LC, Cho TJ, Kon T, et al.: Impaired fracture healing in the absence of TNF-alpha signaling: the role of TNF-alpha in endochondral cartilage resorption. J Bone Miner Res 2003, 18:1584-1592.
53. Hofbauer LC, Lacey DL, Dunstan CR, et al.: Interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999, 25:255-259.
54. Saidenberg-Kermanac'h N, Bessis N, Cohen-Salal M, et al.: Osteoprotegerin and inflammation. Eur Cytokine Netw 2002, 13:144-153.
55. Lam J, Abu-Amer Y, Nelson, et al.: Tumour necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolysis. Ann Rheum Dis 2002, 61(suppl 2):ii82-ii83.
56. Kon T, Cho TJ, Aizawa T, et al.: Expression of osteoprotegerin, receptor-activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. J Bone Miner Res 2001, 16:1004-1014.
57. Jeffcoate WJ, Game F, Cavanagh PR: The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 2005, Aug 10; [Epub ahead of print].
58. Shapiro SA, Stansberry KB, Hill MA, et al.: Normal blood flow response and vasomotion in the diabetic foot. J Diabetes Complications 1998, 12:147-153.
59. Perrien DS, Wahl EC, Hogue WR, et al.: IL-1 and TNF antagonists prevent inhibition of fracture healing by ethanol in rats. Toxicol Sci 2004, 82:656-660.